SCHEMBL3553165

SCHEMBL3553165

COC(=O)C1CCN1C(=O)c1ccc(SC)c(OC(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 2/20 0.52
PDE4B Q07343 6/20 0.44
PDE4D Q08499 3/20 0.44
KMT2A Q03164 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ROCK2 O75116 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
FKBP1A P62942 1/20 0.38
LOX P28300 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
FFAR4 Q5NUL3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3544070 0.88 PDK2 (0.41) PDK2PDE4BPDE4DALDH1A1ROCK2
SCHEMBL3549008 0.88 PDK2 (0.41) PDK2PDE4BPDE4DALDH1A1ROCK2
Hydroxyamine SCHEMBL5276780 0.87 PDE4B (0.41) PDK2PDE4BPDE4DALDH1A1FFAR4
Hydroxyamine SCHEMBL5276778 0.87 PDE4B (0.41) PDK2PDE4BPDE4DALDH1A1FFAR4
SCHEMBL3546372 0.86 PDK2 (0.55) PDK2PDE4BPDE4DKMT2AALDH1A1
SCHEMBL3551107 0.86 PDK2 (0.55) PDK2PDE4BPDE4DKMT2AALDH1A1
SCHEMBL3551111 0.86 PDK2 (0.55) PDK2PDE4BPDE4DKMT2AALDH1A1
SCHEMBL3546371 0.86 PDK2 (0.55) PDK2PDE4BPDE4DKMT2AALDH1A1
SCHEMBL3549086 0.84 PDK2 (0.53) PDK2PDE4BPDE4DKMT2AALDH1A1
SCHEMBL3549084 0.84 PDK2 (0.53) PDK2PDE4BPDE4DKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PDK2 2445/4885PDE4B 2020/4885PDE4D 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.